Search (News)

Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street

business top

(MENAFN - AsiaNet News) Clear Street kept a 'Buy' rating, cut its price target to $45 from $50, and said its core thesis remains intact. The FDA said more evidence is needed to support approval of ...
2026-02-09 22:09:39